Drug Profile
KP 100
Latest Information Update: 26 Jul 2000
Price :
$50
*
At a glance
- Originator Kinetek Pharmaceuticals
- Class Antihyperglycaemics
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 26 Jul 2000 Discontinued-I for Type-2 diabetes mellitus in Canada (Unknown route)
- 10 Feb 1999 Phase-I clinical trials for Type-2 diabetes mellitus in Canada (Unknown route)
- 27 Jul 1998 New profile